Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.60 |
| ▸ | NPC1 | O15118 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189013 | 0.86 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL27163351 | 0.86 | CYP2E1 (0.60) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL30948341 | 0.86 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL30948112 | 0.85 | NPC1 (0.48) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL1545102 | 0.85 | NOTUM (0.59) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL1221187 | 0.82 | PPARD (0.47) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL9901825 | 0.82 | CA12 (0.45) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL30948111 | 0.82 | CA12 (0.45) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL30948125 | 0.81 | NPC1 (0.41) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 | |
| SCHEMBL27587165 | 0.81 | MAPT (0.41) | RAB9ANPC1SMN1; SMN2L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4329889-A1 | IL4I1 INHIBITORS AND METHODS OF USE | Merck Sharp & Dohme LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232333-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20190077777-A1 | NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF | XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) | 2019-03-14 | — | — | US | disclosed |
| US-9738673-B1 | Ferrocene derivative, preparation method and use thereof | XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) | 2017-08-22 | — | — | US | disclosed |
| US-9738673-B1 | Ferrocene derivative, preparation method and use thereof | XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) | 2017-08-22 | — | — | US | disclosed |
| US-9434741-B2 | Thieno[2,3-d]pyrimidine derivatives, preparation method and use thereof | FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-06 | — | — | US | disclosed |
| US-9434741-B2 | Thieno[2,3-d]pyrimidine derivatives, preparation method and use thereof | FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2835372-B1 | THIOPHENE [2, 3-D]PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | FUJIAN MATTER STRUCTURE (CN) | 2016-05-04 | — | — | EP | disclosed |
| EP-2752413-B1 | QUINAZOLINE DERIVATIVE AND APPLICATION THEREOF | FUJIAN MATTER STRUCTURE (CN) | 2016-03-23 | — | — | EP | disclosed |
| US-20140221402-A1 | QUINAZOLINE DERIVATIVE AND APPLICATION THEREOF | FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (JP) | 2014-08-07 | — | — | US | disclosed |
| US-20140221402-A1 | QUINAZOLINE DERIVATIVE AND APPLICATION THEREOF | FUJIAN INSTITUTE OF RESEARCH ON THE STRUCTURE OF MATTER, CHINESE ACADEMY OF SCIENCES (JP) | 2014-08-07 | — | — | US | disclosed |
| EP-2752413-A1 | QUINAZOLINE DERIVATIVE AND APPLICATION THEREOF | Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences (CN) | 2014-07-09 | — | — | EP | disclosed |
| WO-2014043866-A1 | THIOPHENE [2, 3-D] PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | 中国科学院福建物质结构研究所 (CN) | 2014-03-27 | — | — | WO | disclosed |
| WO-2013143319-A1 | QUINAZOLINE DERIVATIVE AND USAGE THEREOF | 中国科学院福建物质结构研究所 (CN) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013143057-A1 | QUINAZOLINE DERIVATIVE AND APPLICATION THEREOF | 中国科学院福建物质结构研究所 (CN) | 2013-10-03 | — | — | WO | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221402-A1 | QUINAZOLINE DERIVATIVE AND APPLICATION THEREOF | ERBB4, EGFR, ERBB2 | RAB9A 1800/4885NPC1 1176/4885SMN1; SMN2 4645/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | RAB9A 1698/4885NPC1 418/4885SMN1; SMN2 1096/4885 |
| US-20190077777-A1 | NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR3, NAPRT | RAB9A 1833/4885NPC1 416/4885SMN1; SMN2 2249/4885 |
| US-20240246937-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | RAB9A 3769/4885NPC1 2807/4885SMN1; SMN2 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.